In Situ Generation of Claudin18.2-Specific CAR-T Cells via Lipid Nanoparticle-Mediated mRNA Delivery.
Chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable clinical success in hematological malignancies; however, its broader application is limited by high manufacturing costs and insufficient efficacy against solid tumors. To overcome these challenges, an in situ CAR-T cell generation strategy was devel...